Literature DB >> 28598205

Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls.

Aylin Yilmaz1, Kaj Blennow2,3, Lars Hagberg1, Staffan Nilsson4, Richard W Price5, Judith Schouten6, Serena Spudich7, Jonathan Underwood8, Henrik Zetterberg2,3,9, Magnus Gisslén1.   

Abstract

INTRODUCTION: Several CSF biomarkers of neuronal injury have been studied in people living with HIV. At this time, the most useful is the light subunit of the neurofilament protein (NFL). This major structural component of myelinated axons is essential to maintain axonal caliber and to facilitate effective nerve conduction. CSF concentrations of NFL provide a sensitive marker of CNS injury in a number of neurological diseases, including HIV-related neuronal injury. Areas Covered: In this review, the authors describe CSF NFL concentrations across the spectrum of HIV-infection, from its early acute phase to severe immunosuppression, with and without neurological conditions, and with and without antiretroviral treatment (n = 516). Furthermore, in order to provide more precise estimates of age-related upper limits of CSF NFL concentrations, the authors present data from a large number (n = 359) of HIV-negative controls. Expert Commentary: Recently a new ultrasensitive diagnostic assay for quantification of NFL in plasma has been developed, providing a convenient way to assess neuronal damage without having to perform a lumbar puncture. This review also considers our current knowledge of plasma NFL in HIV CNS infection.

Entities:  

Keywords:  HIV; biomarker; cerebrospinal fluid; neurodegeneration; neurofilament light

Mesh:

Substances:

Year:  2017        PMID: 28598205     DOI: 10.1080/14737159.2017.1341313

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  47 in total

1.  Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals.

Authors:  Thomas A Premeaux; Michelle L D'Antoni; Mohamed Abdel-Mohsen; Satish K Pillai; Kalpana J Kallianpur; Beau K Nakamoto; Melissa Agsalda-Garcia; Bruce Shiramizu; Cecilia M Shikuma; Magnus Gisslén; Richard W Price; Victor Valcour; Lishomwa C Ndhlovu
Journal:  J Neurovirol       Date:  2018-11-26       Impact factor: 2.643

2.  No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Authors:  Edwina J Wright; Birgit Grund; Kevin R Robertson; Lucette Cysique; Bruce J Brew; Gary L Collins; Mollie Poehlman-Roediger; Michael J Vjecha; Augusto César Penalva de Oliveira; Barbara Standridge; Cate Carey; Anchalee Avihingsanon; Eric Florence; Jens D Lundgren; Alejandro Arenas-Pinto; Nicolas J Mueller; Alan Winston; Moses S Nsubuga; Luxshimi Lal; Richard W Price
Journal:  AIDS       Date:  2018-05-15       Impact factor: 4.177

3.  Elevated CSF neurofilament light chain concentration in a patient with facial onset sensory and motor neuronopathy.

Authors:  Kristin S Lange; André Maier; Christoph Leithner
Journal:  Neurol Sci       Date:  2019-08-06       Impact factor: 3.307

4.  Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.

Authors:  Marie-Angélique De Scheerder; Clarissa Van Hecke; Henrik Zetterberg; Dietmar Fuchs; Nele De Langhe; Sofie Rutsaert; Bram Vrancken; Wim Trypsteen; Ytse Noppe; Bea Van Der Gucht; Jolanda Pelgrom; Filip Van Wanzeele; Sarah Palmer; Philippe Lemey; Magnus Gisslén; Linos Vandekerckhove
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

5.  Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).

Authors:  E Merlini; F Iannuzzi; A Calcagno; F Bai; M Trunfio; A d'Arminio Monforte; S Bonora; Giulia Marchetti
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

6.  Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.

Authors:  Lynn Pulliam; Bing Sun; Maja Mustapic; Sahil Chawla; Dimitrios Kapogiannis
Journal:  J Neurovirol       Date:  2019-01-04       Impact factor: 2.643

7.  Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy.

Authors:  Albert M Anderson; Kirk A Easley; Nicole Kasher; Donald Franklin; Robert K Heaton; Henrik Zetterberg; Kaj Blennow; Magnus Gisslen; Scott L Letendre
Journal:  J Neurovirol       Date:  2018-08-13       Impact factor: 2.643

8.  Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury.

Authors:  Wei Jiang; Zhenwu Luo; Sophie Stephenson; Hong Li; Clara Di Germanio; Philip J Norris; Dietmar Fuchs; Henrik Zetterberg; Magnus Gisslen; Richard W Price
Journal:  J Infect Dis       Date:  2021-05-20       Impact factor: 5.226

9.  Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection.

Authors:  Albert M Anderson; Jeong Hoon Jang; Kirk A Easley; Dietmar Fuchs; Magnus Gisslen; Henrik Zetterberg; Kaj Blennow; Ronald J Ellis; Donald Franklin; Robert K Heaton; Igor Grant; Scott L Letendre
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-15       Impact factor: 3.731

10.  Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy.

Authors:  Beret Amundson; Lillin Lai; Mark J Mulligan; Yong Xu; Zidou Zheng; Suprateek Kundu; Jeffrey L Lennox; Drenna Waldrop-Valverde; Donald Franklin; Alison Swaims-Kohlmeier; Scott L Letendre; Albert M Anderson
Journal:  J Neuroimmunol       Date:  2020-04-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.